Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2

Cancer Science

Volumn 98, Issue 2, 2007, Pages 231-239

  Tamura, Ai ^a   Wakabayashi, Kanako ^a   Onishi, Yuko ^a   Takeda, Misako ^b   Ikegami, Yoji ^b   Sawada, Seigo ^c   Tsuji, Masahisa ^d   Matsuda, Yoichi ^e   Ishikawa, Toshihisa ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^c YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^d Chromosome Science Labo   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYLCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; MITOXANTRONE; SN 343; SN 348; SN 349; SN 351; SN 352; SN 353; SN 355; SN 364; SN 392; SN 397; SN 398; SN 443; SN 444; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELLULAR DISTRIBUTION; CHROMOSOME 12P; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG STRUCTURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MAPPING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; VALIDATION PROCESS; WILD TYPE;

ADENOSINE TRIPHOSPHATASES; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL LINE; CHROMOSOMES, HUMAN; DNA, COMPLEMENTARY; DRUG RESISTANCE; GENE EXPRESSION; GENOME, HUMAN; GLUTAMINE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR STRUCTURE; MUTATION; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; VALINE;

EID: 33845655480     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00371.x     Document Type: Article

References (36)

1. Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15 6 65-70.
2. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-9.
3. Miyake K, Mickley L, Litman T et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8-13.
4. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001; 1520: 234-41.
5. Henriksen U, Fog JU, Litman T, Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem 2005; 280: 36 9 26-34.
6. Kage K, Fujita T, Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 2005; 96: 866-72.
7. Wakabayashi K, Nakagawa H, Adachi T et al. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: A new approach using the flp recombinase system. J Exp Ther Oncol 2006; 5: 205-22.
8. Jonker JW, Buitelaar M, Wagenaar E et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15 6 49-54.
9. Maliepaard M, van Gastelen MA, de Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63.
10. Ross DD, Yang W, Abruzzo LV et al. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91: 429-33.
11. Brangi M, Litman T, Ciotti M et al. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59: 5938-46.
12. Kawabata S, Oka M, Shiozawa K et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280: 1216-23.
13. Nakatomi K, Yoshikawa M, Oka M et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288: 827-32.
14. Yoshikawa M, Ikegami Y, Sano K et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 2004; 4: 25-35.
15. Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biol Ther 2005; 4: 187-94.
16. Tamura A, Watanabe M, Saito H et al. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: Identification of alleles that are defective in porphyrin transport. Mol Pharmacol 2006; 70: 287-96.
17. Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y. Functional SNPs of the breast cancer resistance protein: Therapeutic effects and inhibitor development. Cancer Lett 2006; 234: 73-80.
18. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006; 234: 90-106.
19. Ishikawa T, Tamura A, Saito H, Wakabayashi K, Nakagawa H. Pharmacogenomics of the human ABC transporter ABCG2: From functional evaluation to drug molecular design. Naturwissenschaften 2005; 92: 451-63.
20. Backstrom G, Taipalensuu J, Melhus H et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003; 18: 359-64.
21. Bosch TM, Kjellberg LM, Bouwers A et al. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 2005; 5: 123-31.
22. de Jong FA, Marsh S, Mathijssen RH et al. ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004; 10: 5889-94.
23. Honjo Y, Morisaki K, Huff LM et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 2002; 1: 696-702.
24. Iida A, Saito S, Sekine A et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 2002; 47: 285-310.
25. Imai Y, Nakane M, Kage K et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1: 611-16.
26. Itoda M, Saito Y, Shirao K et al. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet 2003; 18: 212-17.
27. Kobayashi D, Ieiri I, Hirota T et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005; 33: 94-101.
28. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2004; 109: 238-46.
29. Zamber CP, Lamba JK, Yasuda K et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003; 13: 19-28.
30. Morisaki K, Robey RW, Ozvegy-Laczka C et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005; 56: 161-72.
31. Kondo C, Suzuki H, Itoda M et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004; 21: 1895-903.
32. Yoshikawa M, Ikegami Y, Hayasaka S et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 2004; 110: 921-7.
33. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett 2006; 234: 81-9.
34. Matsuda Y, Chapman VM. Application of fluorescence in situ hybridization in genome analysis of the mouse. Electrophoresis 1995; 16: 261-72.
35. Ishikawa T, Kasamatsu S, Hagiwara Y, Mitomo H, Kato R, Sumino Y. Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab Pharmacokinet 2003; 18: 194-202.
36. Sparreboom A, Gelderblom H, Marsh S et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin Pharmacol Ther 2004; 76: 38-44.